<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04894227</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-nCOV-4001</org_study_id>
    <nct_id>NCT04894227</nct_id>
  </id_info>
  <brief_title>Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults</brief_title>
  <official_title>A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac） in Health Adults Aged 26-45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Research and Development Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double-blind, randomized phase Ⅳ clinical trial of the inactivated SARS-CoV-2&#xD;
      vaccine (CoronaVac）manufactured by Sinovac Research &amp; Development Co., Ltd. The purpose of&#xD;
      this study is to evaluate the lot-to-lot consistency, immunogenicity and safety of CoronaVac&#xD;
      in healthy adults aged 26-45 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blind, randomized phase Ⅳ clinical trial in healthy adults aged 26-45&#xD;
      years to evaluate the lot-to-lot consistency, immunogenicity and safety of the&#xD;
      commercial-scale CoronaVac in healthy adults aged 26-45 years .The experimental vaccine was&#xD;
      manufactured by Sinovac Research &amp; Development Co.,Ltd. A total of 1080 healthy subjects aged&#xD;
      26 to 45 years old will be enrolled.The subjects will be randomly divided into three groups&#xD;
      in a ratio of 1:1:1 to received two doses of vaccine on day 0 and day 28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 11, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 11, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean titer(GMT) of neutralizing antibody to live SARS-CoV-2 in susceptible population</measure>
    <time_frame>Day 28 after the second dose</time_frame>
    <description>GMT of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose in susceptible population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate of the neutralizing antibody to live SARS-CoV-2 in total population</measure>
    <time_frame>Day 28 after the second dose</time_frame>
    <description>Seroconversion rate of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose in total population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity rate of the neutralizing antibody to live SARS-CoV-2 in total population</measure>
    <time_frame>Day 28 after the second dose</time_frame>
    <description>Seropositivity rate of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose in total population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of the neutralizing antibody to live SARS-CoV-2 in total population</measure>
    <time_frame>Day 28 after the second dose</time_frame>
    <description>GMT of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose in total population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean increase (GMI) of the neutralizing antibody to live SARS-CoV-2 in total population</measure>
    <time_frame>Day 28 after the second dose</time_frame>
    <description>GMI of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose in total population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate of the neutralizing antibody to live SARS-CoV-2 in susceptible population</measure>
    <time_frame>Day 28 after the second dose</time_frame>
    <description>Seroconversion rate of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose in susceptible population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositive rate of the neutralizing antibody to live SARS-CoV-2 in susceptible population</measure>
    <time_frame>Day 28 after the second dose</time_frame>
    <description>Seropositive rate of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose in susceptible population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMI of the neutralizing antibody to live SARS-CoV-2 in susceptible population</measure>
    <time_frame>Day 28 after the second dose</time_frame>
    <description>GMI of the neutralizing antibody to live SARS-CoV-2 at day 28 after the second dose in susceptible population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity rate of anti-SARS-CoV-2 S antibody</measure>
    <time_frame>Day 28 after the second dose</time_frame>
    <description>Seropositivity rate of the anti-SARS-CoV-2 S antibody at day 28 after the second dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate of anti-SARS-CoV-2 S antibody</measure>
    <time_frame>Day 28 after the second dose</time_frame>
    <description>Seroconversion rate of the anti-SARS-CoV-2 S antibody at day 28 after the second dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean concentration (GMC) of anti-SARS-CoV-2 S antibody</measure>
    <time_frame>Day 28 after the second dose</time_frame>
    <description>GMC of the anti-SARS-CoV-2 S antibody at day 28 after the second dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMI of anti-SARS-CoV-2 S antibody</measure>
    <time_frame>Day 28 after the second dose</time_frame>
    <description>GMI of the anti-SARS-CoV-2 S antibody at day 28 after the second dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse reactions after vaccination</measure>
    <time_frame>From the beginning of the vaccination to 28 days after the second dose</time_frame>
    <description>Incidence of adverse reactions from the beginning of the vaccination to 28 days after the second dose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1080</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Inactivated SARS-CoV-2 vaccine Lot 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 1 according to 0,28-day immunization schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactivated SARS-CoV-2 vaccine Lot 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 2 according to 0,28-day immunization schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactivated SARS-CoV-2 vaccine Lot 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (n=360) aged 26-45 years will receive Inactivated SARS-CoV-2 vaccine Lot 3 according to 0,28-day immunization schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated SARS-CoV-2 Vaccine (Vero cell）</intervention_name>
    <description>600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection</description>
    <arm_group_label>Inactivated SARS-CoV-2 vaccine Lot 1</arm_group_label>
    <arm_group_label>Inactivated SARS-CoV-2 vaccine Lot 2</arm_group_label>
    <arm_group_label>Inactivated SARS-CoV-2 vaccine Lot 3</arm_group_label>
    <other_name>CoronaVac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged 26-45;&#xD;
&#xD;
          -  The subjects can understand and voluntarily sign the informed consent form ;&#xD;
&#xD;
          -  Proven legal identity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Travel history / residence history of communities with case reports within 14 days&#xD;
             prior to the study;&#xD;
&#xD;
          -  History of contact with a SARS-CoV-2 infection (positive in nucleic acid test) within&#xD;
             14 days prior to the study;&#xD;
&#xD;
          -  Have contacted patients with fever or respiratory symptoms from communities with case&#xD;
             reports within 14 days prior to the study;&#xD;
&#xD;
          -  Two or more cases of fever and / or respiratory symptoms in a small contact area of&#xD;
             volunteers, such as home, office etc. within 14 days prior to the study;&#xD;
&#xD;
          -  History of SARS-CoV-2 infection or receiving COVID-19 vaccine;&#xD;
&#xD;
          -  History of asthma, history of allergy to the vaccine or vaccine components, or serious&#xD;
             adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema;&#xD;
&#xD;
          -  Congenital malformations or developmental disorders, genetic defects, severe&#xD;
             malnutrition, etc.;&#xD;
&#xD;
          -  Autoimmune disease (Systemic lupus erythematosus)or immunodeficiency /&#xD;
             immunosuppression(HIV,history after organ transplantation)&#xD;
&#xD;
          -  Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes&#xD;
             that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc.;&#xD;
&#xD;
          -  Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;&#xD;
&#xD;
          -  Thyroid disease or history of thyroidectomy, spleenlessness, functional&#xD;
             spleenlessness, spleenlessness or splenectomy resulting from any condition;&#xD;
&#xD;
          -  Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors,&#xD;
             blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;&#xD;
&#xD;
          -  Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding&#xD;
             allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis&#xD;
             superficial corticosteroid therapy) in the past 6 months;&#xD;
&#xD;
          -  History of alcohol or drug abuse;&#xD;
&#xD;
          -  Receipt of blood products within in the past 3 months；&#xD;
&#xD;
          -  Receipt of other investigational drugs in the past 30 days；&#xD;
&#xD;
          -  Receipt of attenuated live vaccines in the past 14 days;&#xD;
&#xD;
          -  Receipt of inactivated or subunit vaccines in the past 7 days;&#xD;
&#xD;
          -  Onset of various acute or chronic diseases within 7 days prior to the study;&#xD;
&#xD;
          -  Axillary temperature &gt;37.0°C;&#xD;
&#xD;
          -  Already pregnant (including a positive urine pregnancy test) or are breastfeeding,&#xD;
             planning to get pregnant within 2 months;&#xD;
&#xD;
          -  The subjects participated in other clinical trials during the follow-up period, or&#xD;
             will be planned within 3 months;&#xD;
&#xD;
          -  According to the investigator's judgment, the subject has any other factors that are&#xD;
             not suitable for participating in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>26 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongxing Pan, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial Center for Disease Prevention and Control</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jingliang Wu</name>
      <address>
        <city>Huai'an</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

